Risk of cardiovascular disease associated with exposure to abacavir among individuals with HIV

A systematic review and meta-analyses of results from 17 epidemiologic studies

Kunchok Dorjee, Tsering Choden, Sanjiv M. Baxi, Craig Steinmaus, Arthur L. Reingold

Research output: Contribution to journalArticle

Abstract

Objectives: Abacavir's potential to cause cardiovascular disease (CVD) among people living with HIV (PLWH) is debated. We conduct a systematic review and meta-analyses to assess CVD risk from recent and cumulative abacavir exposure. Methods: We searched Medline, Embase, Web of Science, abstracts from Conference on Retroviruses and Opportunistic Infections, and International AIDS Society/AIDS Conferences and bibliographies of review articles to identify research studies published through 2018 on CVD risk associated with abacavir exposure among PLWH. Studies assessing risk of CVD associated with recent (exposure within last 6 months) or cumulative abacavir exposure across all age-groups were eligible. Risks were quantified using fixed- and random-effects models. Results: Of 378 unique citations, 68 full-text research articles and abstracts were reviewed. Seventeen studies assessed risk of CVD from recent or cumulative abacavir exposure. Summary relative risk (sRR) is increased for recent exposure (n=16 studies, sRR=1.61; 95% confidence interval: 1.48–1.75), higher in antiretroviral-therapy-naive population (n=5, 1.91; 1.48–2.46) and all studies reported RR>1. The sRR for recent exposure was similarly increased for the outcome of acute myocardial infarction, and for studies that adjusted for substance abuse, smoking, prior CVD, traditional CVD risk factors, and CD4 cell-count/HIV viral load. The sRR was increased for cumulative abacavir exposure (per year) (n=4, 1.12; 1.05–1.20) but no increase was seen after adjusting for recent exposure (n=5, 1.00; 0.93–1.08). Conclusions: Our findings suggest an increased risk of CVD from recent abacavir exposure. The risk remained elevated after adjusting for potential confounders. Further investigations are needed to understand CVD risk from cumulative exposure.

Original languageEnglish (US)
JournalInternational Journal of Antimicrobial Agents
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Meta-Analysis
Epidemiologic Studies
Cardiovascular Diseases
HIV
abacavir
Bibliography
CD4 Lymphocyte Count
Viral Load
Research
Substance-Related Disorders
Acquired Immunodeficiency Syndrome
Age Groups
Smoking
Myocardial Infarction
Confidence Intervals

Keywords

  • Abacavir
  • Cardiovascular disease
  • Human immunodeficiency virus

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

@article{579743e548d24c6a87188e4745493212,
title = "Risk of cardiovascular disease associated with exposure to abacavir among individuals with HIV: A systematic review and meta-analyses of results from 17 epidemiologic studies",
abstract = "Objectives: Abacavir's potential to cause cardiovascular disease (CVD) among people living with HIV (PLWH) is debated. We conduct a systematic review and meta-analyses to assess CVD risk from recent and cumulative abacavir exposure. Methods: We searched Medline, Embase, Web of Science, abstracts from Conference on Retroviruses and Opportunistic Infections, and International AIDS Society/AIDS Conferences and bibliographies of review articles to identify research studies published through 2018 on CVD risk associated with abacavir exposure among PLWH. Studies assessing risk of CVD associated with recent (exposure within last 6 months) or cumulative abacavir exposure across all age-groups were eligible. Risks were quantified using fixed- and random-effects models. Results: Of 378 unique citations, 68 full-text research articles and abstracts were reviewed. Seventeen studies assessed risk of CVD from recent or cumulative abacavir exposure. Summary relative risk (sRR) is increased for recent exposure (n=16 studies, sRR=1.61; 95{\%} confidence interval: 1.48–1.75), higher in antiretroviral-therapy-naive population (n=5, 1.91; 1.48–2.46) and all studies reported RR>1. The sRR for recent exposure was similarly increased for the outcome of acute myocardial infarction, and for studies that adjusted for substance abuse, smoking, prior CVD, traditional CVD risk factors, and CD4 cell-count/HIV viral load. The sRR was increased for cumulative abacavir exposure (per year) (n=4, 1.12; 1.05–1.20) but no increase was seen after adjusting for recent exposure (n=5, 1.00; 0.93–1.08). Conclusions: Our findings suggest an increased risk of CVD from recent abacavir exposure. The risk remained elevated after adjusting for potential confounders. Further investigations are needed to understand CVD risk from cumulative exposure.",
keywords = "Abacavir, Cardiovascular disease, Human immunodeficiency virus",
author = "Kunchok Dorjee and Tsering Choden and Baxi, {Sanjiv M.} and Craig Steinmaus and Reingold, {Arthur L.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.ijantimicag.2018.07.010",
language = "English (US)",
journal = "International Journal of Antimicrobial Agents",
issn = "0924-8579",
publisher = "Elsevier",

}

TY - JOUR

T1 - Risk of cardiovascular disease associated with exposure to abacavir among individuals with HIV

T2 - A systematic review and meta-analyses of results from 17 epidemiologic studies

AU - Dorjee, Kunchok

AU - Choden, Tsering

AU - Baxi, Sanjiv M.

AU - Steinmaus, Craig

AU - Reingold, Arthur L.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objectives: Abacavir's potential to cause cardiovascular disease (CVD) among people living with HIV (PLWH) is debated. We conduct a systematic review and meta-analyses to assess CVD risk from recent and cumulative abacavir exposure. Methods: We searched Medline, Embase, Web of Science, abstracts from Conference on Retroviruses and Opportunistic Infections, and International AIDS Society/AIDS Conferences and bibliographies of review articles to identify research studies published through 2018 on CVD risk associated with abacavir exposure among PLWH. Studies assessing risk of CVD associated with recent (exposure within last 6 months) or cumulative abacavir exposure across all age-groups were eligible. Risks were quantified using fixed- and random-effects models. Results: Of 378 unique citations, 68 full-text research articles and abstracts were reviewed. Seventeen studies assessed risk of CVD from recent or cumulative abacavir exposure. Summary relative risk (sRR) is increased for recent exposure (n=16 studies, sRR=1.61; 95% confidence interval: 1.48–1.75), higher in antiretroviral-therapy-naive population (n=5, 1.91; 1.48–2.46) and all studies reported RR>1. The sRR for recent exposure was similarly increased for the outcome of acute myocardial infarction, and for studies that adjusted for substance abuse, smoking, prior CVD, traditional CVD risk factors, and CD4 cell-count/HIV viral load. The sRR was increased for cumulative abacavir exposure (per year) (n=4, 1.12; 1.05–1.20) but no increase was seen after adjusting for recent exposure (n=5, 1.00; 0.93–1.08). Conclusions: Our findings suggest an increased risk of CVD from recent abacavir exposure. The risk remained elevated after adjusting for potential confounders. Further investigations are needed to understand CVD risk from cumulative exposure.

AB - Objectives: Abacavir's potential to cause cardiovascular disease (CVD) among people living with HIV (PLWH) is debated. We conduct a systematic review and meta-analyses to assess CVD risk from recent and cumulative abacavir exposure. Methods: We searched Medline, Embase, Web of Science, abstracts from Conference on Retroviruses and Opportunistic Infections, and International AIDS Society/AIDS Conferences and bibliographies of review articles to identify research studies published through 2018 on CVD risk associated with abacavir exposure among PLWH. Studies assessing risk of CVD associated with recent (exposure within last 6 months) or cumulative abacavir exposure across all age-groups were eligible. Risks were quantified using fixed- and random-effects models. Results: Of 378 unique citations, 68 full-text research articles and abstracts were reviewed. Seventeen studies assessed risk of CVD from recent or cumulative abacavir exposure. Summary relative risk (sRR) is increased for recent exposure (n=16 studies, sRR=1.61; 95% confidence interval: 1.48–1.75), higher in antiretroviral-therapy-naive population (n=5, 1.91; 1.48–2.46) and all studies reported RR>1. The sRR for recent exposure was similarly increased for the outcome of acute myocardial infarction, and for studies that adjusted for substance abuse, smoking, prior CVD, traditional CVD risk factors, and CD4 cell-count/HIV viral load. The sRR was increased for cumulative abacavir exposure (per year) (n=4, 1.12; 1.05–1.20) but no increase was seen after adjusting for recent exposure (n=5, 1.00; 0.93–1.08). Conclusions: Our findings suggest an increased risk of CVD from recent abacavir exposure. The risk remained elevated after adjusting for potential confounders. Further investigations are needed to understand CVD risk from cumulative exposure.

KW - Abacavir

KW - Cardiovascular disease

KW - Human immunodeficiency virus

UR - http://www.scopus.com/inward/record.url?scp=85054408084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054408084&partnerID=8YFLogxK

U2 - 10.1016/j.ijantimicag.2018.07.010

DO - 10.1016/j.ijantimicag.2018.07.010

M3 - Article

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

SN - 0924-8579

ER -